血清对棘白菌素体外药敏试验的影响。
Effects of serum on in vitro susceptibility testing of echinocandins.
作者信息
Odabasi Zekaver, Paetznick Victor, Rex John H, Ostrosky-Zeichner Luis
机构信息
Marmara University, Tophanelioglu caddesi, No:13, 34662 Altunizade, Istanbul, Turkey.
出版信息
Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6. doi: 10.1128/AAC.01589-06. Epub 2007 Sep 4.
Abstract
The effects of protein binding on the activities of caspofungin, anidulafungin, and micafungin were evaluated against Candida and Aspergillus species. Adding human serum sharply increased the MICs of micafungin and anidulafungin and modestly affected the MIC of caspofungin. The increase in MICs does not appear consistent with the rate of protein binding for the three compounds.
摘要
评估了蛋白结合对卡泊芬净、阿尼芬净和米卡芬净抗念珠菌属和曲霉属活性的影响。加入人血清后，米卡芬净和阿尼芬净的最低抑菌浓度（MIC）大幅增加，而卡泊芬净的MIC受到轻微影响。MIC的增加似乎与这三种化合物的蛋白结合率不一致。
相似文献
1
Effects of serum on in vitro susceptibility testing of echinocandins.
Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6. doi: 10.1128/AAC.01589-06. Epub 2007 Sep 4.
2
Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
Mycoses. 2012 Mar;55(2):156-60. doi: 10.1111/j.1439-0507.2011.02050.x. Epub 2011 Jun 12.
3
Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins.
Med Mycol. 2010 Sep;48(6):858-61. doi: 10.3109/13693781003586943.
4
The echinocandins.
Pharmacotherapy. 2007 Mar;27(3):369-88. doi: 10.1592/phco.27.3.369.
5
Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Clin Microbiol Infect. 2009 Mar;15(3):274-9. doi: 10.1111/j.1469-0691.2008.02660.x. Epub 2009 Feb 5.
6
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
J Antimicrob Chemother. 2012 Sep;67(9):2195-202. doi: 10.1093/jac/dks180. Epub 2012 May 25.
7
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15.
8
In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
Antimicrob Agents Chemother. 2011 Jun;55(6):3031-5. doi: 10.1128/AAC.01569-10. Epub 2011 Mar 21.
9
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
Antimicrob Agents Chemother. 2009 Jul;53(7):3108-11. doi: 10.1128/AAC.00160-09. Epub 2009 Apr 20.
10
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Antimicrob Agents Chemother. 2005 Dec;49(12):5157-9. doi: 10.1128/AAC.49.12.5157-5159.2005.
引用本文的文献
1
Targeting ceramide synthases for the development of new antifungals.
Structure. 2025 Jun 12. doi: 10.1016/j.str.2025.05.016.
2
Echinocandin persistence directly impacts the evolution of resistance and survival of the pathogenic fungus .
mBio. 2024 Apr 10;15(4):e0007224. doi: 10.1128/mbio.00072-24. Epub 2024 Mar 19.
3
Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints.
J Antimicrob Chemother. 2023 Jun 1;78(6):1386-1394. doi: 10.1093/jac/dkad096.
4
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):770-782. doi: 10.1002/psp4.12949. Epub 2023 Mar 13.
5
Human Tissue Distribution of Anidulafungin and Micafungin.
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0016921. doi: 10.1128/AAC.00169-21.
6
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex.
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00275-20.
7
Caspofungin-Mediated Growth Inhibition and Paradoxical Growth in Aspergillus fumigatus Involve Fungicidal Hyphal Tip Lysis Coupled with Regenerative Intrahyphal Growth and Dynamic Changes in β-1,3-Glucan Synthase Localization.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00710-17. Print 2017 Oct.
8
Special Issue: Novel Antifungal Drug Discovery.
J Fungi (Basel). 2016 Dec;2(4). doi: 10.3390/jof2040033. Epub 2016 Dec 14.
9
Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5631-9. doi: 10.1128/AAC.00324-16. Print 2016 Oct.
10
Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.
Antimicrob Agents Chemother. 2015 Dec 7;60(3):1226-33. doi: 10.1128/AAC.02026-15.
本文引用的文献
1
In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.
Antimicrob Agents Chemother. 2002 Dec;46(12):3846-53. doi: 10.1128/AAC.46.12.3846-3853.2002.
2
Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.
Antimicrob Agents Chemother. 2000 Dec;44(12):3302-5. doi: 10.1128/AAC.44.12.3302-3305.2000.
3
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.
J Clin Microbiol. 2000 Sep;38(9):3457-9. doi: 10.1128/JCM.38.9.3457-3459.2000.
4
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Antimicrob Agents Chemother. 2000 Jan;44(1):57-62. doi: 10.1128/AAC.44.1.57-62.2000.
5
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44. doi: 10.1128/AAC.41.11.2339.
6
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
Antimicrob Agents Chemother. 1997 Nov;41(11):2326-32. doi: 10.1128/AAC.41.11.2326.
7
Influence of serum protein binding on the in vitro activity of anti-fungal agents.
Infection. 1995 Sep-Oct;23(5):292-7. doi: 10.1007/BF01716289.
8
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
Antimicrob Agents Chemother. 1994 Jul;38(7):1480-9. doi: 10.1128/AAC.38.7.1480.
9
The relevance of pharmacokinetics to in-vitro models: protein binding--does it matter?
J Antimicrob Chemother. 1985 Jan;15 Suppl A:77-83. doi: 10.1093/jac/15.suppl_a.77.
10
Influence of plasma protein binding on the brain uptake of an antifungal agent, terbinafine, in rats.
J Pharm Pharmacol. 1989 Oct;41(10):700-4. doi: 10.1111/j.2042-7158.1989.tb06344.x.
Zotero 插件